The burgeoning landscape of treatment for obesity and type 2 metabolic disorder is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant differences in their pharmacological profiles and clinical study results are emerging. Retat… Read More

Showing promise in the arena of excess body fat treatment, retatrutide is a distinct strategy. Unlike many current medications, retatrutide functions as a double agonist, simultaneously affecting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic hormone (GIP) sensors. This simultaneous engagement encourages multiple adva… Read More